TYK Medicines, Inc

TYK Medicines' TY-9591 Shows Superior Efficacy Over Osimertinib in Treating Brain Metastases from EGFR-Mutated Lung Cancer

2 months ago

• TYK Medicines has announced positive Phase II trial results showing TY-9591 demonstrated statistically significant superiority over osimertinib in treating brain metastases from EGFR-mutated lung cancer. • The pivotal study met its primary endpoint of intracranial objective response rate (iORR), with TY-9591 showing strong positive results across all patient subgroups while maintaining a favorable safety profile. • TYK Medicines plans to submit a New Drug Application to China's National Medical Products Administration, positioning TY-9591 as the first drug to demonstrate superiority over osimertinib in this indication.